

FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-2978
WWW.FULBRIGHT.COM

TWOHLERS@FULBRIGHT.COM
DIRECT DIAL: (512) 536-5654

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598


February 3, 2010

Commissioner for Patents
Attn: Tekchand Saidha, Examiner
P.O. Box 1450
Alexandria, Virginia 22313-1450

CERTIFICATE OF ELECTRONIC TRANSMISSION
7 C.F.R. § 1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

February 3, 2010
Date


Travis M. Wohlers

RE: *U.S. Patent Application No. 10/518,599 entitled "ACE2 ACTIVATION FOR TREATMENT OF HEART, LUNG AND KIDNEY DISEASE AND HYPERTENSION" – Joseph M. Penninger et al.*
Confirmation No.: 8087
Our reference: SONN:064US

Dear Examiner Saidha:

After reviewing each of the Office Actions and the Notice of Allowability, it has come to our attention that the Information Disclosure Statement, Form PTO-1449 and five references submitted on May 31, 2005, were apparently never signed off by an Examiner.

For your convenience we have enclosed a copy of the Information Disclosure Statement and Form PTO-1449 that were filed with the Patent and Trademark Office (PTO) on May 31, 2005. The copies of the references previously submitted have not been enclosed. Please let us know if you would like us to resubmit those as well.

Please review and approve this Information Disclosure Statement. If you need additional information, please let us know.

Thank you for your assistance in this matter.

Very truly yours,


Travis M. Wohlers

TMW/jst
Attachment

55590167.1

AUSTIN • BEIJING • DALLAS • DENVER • DUBAI • HONG KONG • HOUSTON • LONDON • LOS ANGELES • MINNEAPOLIS
MUNICH • NEW YORK • RIYADH • SAN ANTONIO • ST. LOUIS • WASHINGTON DC

REJOI PCT/PTO 31 MAY 2005

PATENT

#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Joseph M. Penninger et al.

Serial No.: 10/518,599

Filed: December 17, 2004

For: ACE2 ACTIVATION FOR TREATMENT
OF HEART, LUNG AND KIDNEY
DISEASE AND HYPERTENSION

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: SONN:064US

EXPRESS MAIL MAILING LABEL
NUMBER EV 414867445 US
DATE OF DEPOSIT May 31, 2005

INFORMATION DISCLOSURE STATEMENT

MS PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/SONN:064US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 31, 2005